Jason Dinges Net Worth

Jason Dinges biography

Dr. Jason R. Dinges Ph.D., J.D. serves as Independent Director of the Company. Dr. Dinges has served as an investment advisor at Morningside Technology Advisory LLC. Prior to that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology and Pharmaceutical practice group from March 2007 to February 2011. Dr. Dinges also serves on the board of directors of various privately held biotechnology companies. Dr. Dinges received his Ph.D. degree in genetics from Iowa State University and a J.D. degree from the University of Iowa College of Law. Dinges’ scientific and legal training and experience in life science investments qualifies him to serve on our Board.

What is the salary of Jason Dinges?

As the Independent Director of Kezar Life Sciences Inc, the total compensation of Jason Dinges at Kezar Life Sciences Inc is $85,934. There are 10 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.

How old is Jason Dinges?

Jason Dinges is 44, he's been the Independent Director of Kezar Life Sciences Inc since 2018. There are 12 older and 2 younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.

What's Jason Dinges's mailing address?

Jason's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Kezar Life Sciences Inc

Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B..., and Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.

What does Kezar Life Sciences Inc do?

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.

Kezar Life Sciences Inc executives and stock owners

Kezar Life Sciences Inc executives and other stock owners filed with the SEC include:

• John Fowler,
  Chief Executive Officer, Director
• Christopher Kirk,
  President, Chief Scientific Officer, Director
• Marc Belsky,
  Chief Financial Officer, Secretary
• John Franklin Fowler,
  Co-Founder, CEO & Director
• Dr. Noreen Roth Henig,
  Chief Medical Officer
• Dr. Christopher J. Kirk,
  Co-Founder, Pres, Chief Scientific Officer & Director
• Jean-Pierre Sommadossi,
  Independent Chairman of the Board
• Graham Cooper,
  Independent Director
• Michael Kauffman,
  Independent Director
• Franklin Berger,
  Independent Director
• Jason Dinges,
  Independent Director
• Elizabeth Garner,
  Independent Director
• Alex Gray,
  IR Contact Officer
• Noreen Henig,
  Chief Medical Officer
• Vassiliki Economides,
  Senior Vice President - Strategy and External Affairs
• Vassiliki Economides,
  Sr. VP of Strategy & External Affairs
• Gitanjali Jain,
  VP of Investor Relations & External Affairs
• Michael Wolfe,
  Director of Fin. & Operations
• Marc L. Belsky,
  CFO & Sec.
• Dr. Jack Taunton Ph.D.,
  Co-Founder
• Talent Investments Ltd Equal,
  10% owner
• Management Company, Llc Abe...,
  10% owner
• Arthur Ma.M. Pappas Life Sc...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Asset Management, Lp Chen B...,
  
• Venture Investments Ltd Mor...,
  
• Ventures, Inc.Chiesi Ventur...,
  
• Therapeutics, Inc.Amgen Inc...,
  
• City Capital Llc Bay,
  10% owner
• Thomas F Steyer,
  
• Niti Goel,
  Chief Medical Officer
• Mark C. Schiller,
  Chief Legal Officer
• Nicholas Michael Mordwinkin,
  Chief Business Officer
• Micki Klearman,
  
• Courtney Wallace,